PrEP May Not Be Working As It Should For Some Users

If your PrEP doesn't seem to be working, the most common reason is missed or inconsistent doses. PrEP only protects when taken on its prescribed schedule, and it takes time to reach full effect. It also never covers other STIs or pregnancy. If you've taken it correctly and still worry, see a clinician for HIV testing and a review of your regimen.

What PrEP is and how it works

PrEP stands for pre-exposure prophylaxis: medicine that an HIV-negative person takes before a possible exposure to keep HIV from taking hold. It prevents infection, a different job from the antiretrovirals someone takes after they already have HIV. The drugs work by flooding your bloodstream and tissues with antiviral medicine so that if the virus arrives, it can't establish a lasting infection.

That mechanism explains why PrEP "isn't working" for some people: the protective drug level has to actually be there when exposure happens. If pills are skipped, or if you start protection too late, the tissue levels aren't high enough to block the virus. PEP is the emergency, after-exposure option, while PrEP is taken on an ongoing basis, so the two aren't interchangeable. If you're unsure which situation you're in, our guide on PrEP vs PEP walks through the difference.

How well PrEP works, and why adherence is the whole game

Taken as prescribed, PrEP reduces the risk of getting HIV from sex by about 99% CDC. For people exposed through injection drug use, the pills lower risk by at least 74% when taken consistently. Those are extraordinary numbers, but the phrase "as prescribed" is doing real work.

The landmark iPrEx study, published in November 2010, first established that a once-daily TDF-FTC tablet reduced HIV acquisition among at-risk men who have sex with men and transgender women, with a 42% overall reduction iPrEx Trial (PMC). That overall figure looks modest next to 99% because of adherence. Among participants who actually had detectable drug in their blood, protection was estimated at greater than 90%. The pills protect well when they're taken; they do nothing in the bottle.

Timing matters too. Protection isn't instant the moment you take the first pill, because the medicine has to build up in the relevant tissue. Maximum protection takes about 7 days for receptive anal sex, and about 21 days for receptive vaginal sex and injection drug use. Someone who relies on PrEP within that build-up window may have a real gap they didn't know about. If you've had a possible exposure during that period, see when to test after exposure for the right timing.

For people who struggle with daily pills, the long-acting options were a breakthrough. In the HPTN 084 trial of cisgender women, HIV infection risk was 88% lower in the injectable cabotegravir group than in the daily oral TDF-FTC group, since a shot every several weeks removes the daily-adherence problem HPTN 084. More than 2.5 million people worldwide received PrEP in 2022, yet it remains underused relative to who could benefit PubMed PrEP for HIV.

How to use PrEP and who it's for

PrEP is for HIV-negative people who have an ongoing chance of exposure, whether through sex with a partner whose status is positive or unknown, multiple partners, a recent bacterial STI, or shared injection equipment. There are now several formats, and the "right" one depends on your body, your routine, and how you're at risk:

• Daily oral Truvada (TDF-FTC): Approved for people at risk through either sex or injection drug use, the most broadly applicable pill.
• Daily oral Descovy: For those at risk through sex only. It's not approved for people assigned female at birth who are at risk through receptive vaginal sex.
• Injectable Apretude (cabotegravir): A shot for people at risk through sex who weigh at least 77 pounds (35 kg), a strong choice if a daily pill is hard to keep up with.
• Injectable lenacapavir (LEN): In 2025 the CDC recommended this option, given as a subcutaneous shot every 6 months, updating the 2021 PrEP Clinical Practice Guideline on the strength of two randomized controlled trials CDC, 2025.

Internationally the menu is similar. WHO has recommended TDF-based oral PrEP since September 2015 for people at substantial risk, added the dapivirine vaginal ring for women in 2021, and recommended long-acting injectable cabotegravir in 2022 WHO. WHO's 2022 implementation guidance also pushed for simplified, differentiated delivery so PrEP fits into people's real lives WHO, 2022.

In practice, starting PrEP means an HIV test first, since you have to be HIV-negative to begin, followed by regular check-ins while you're on it, including repeat HIV testing and kidney monitoring for the pills. Those visits let a clinician catch a problem early and confirm the medicine is doing its job.

Cost and how to get PrEP

PrEP is prescribed by primary care clinics, sexual-health clinics, and many telehealth services, so you don't necessarily need a specialist. People fear cost most, but assistance programs exist specifically to cover the medication and lab work for those who are uninsured or underinsured. If price is what's standing between you and consistent protection, ask the prescriber's office directly. They usually know which program fits your situation.

What PrEP does NOT protect against

Here "PrEP isn't working" is often a misunderstanding rather than a failure. PrEP protects against HIV. It does not protect against other sexually transmitted infections like chlamydia, gonorrhea, or syphilis, and it does nothing for pregnancy. Someone who picks up gonorrhea while on PrEP doesn't have a broken pill; they have an infection PrEP was never designed to stop.

A second common mistake is treating PrEP like a morning-after fix. It only works taken on an ongoing schedule, and taking a pill the day after a risky encounter does not provide reliable protection. That's the scenario PEP exists for. Because PrEP leaves other STIs on the table, people on PrEP should keep up routine screening; here's how to get tested on a regular schedule.

How PrEP fits with the rest of HIV prevention

PrEP works best as one layer in a stack. Condoms add protection against the STIs PrEP misses and against pregnancy. Routine STI testing catches infections early. And vaccines, like those for hepatitis B and HPV, cover threats outside PrEP's reach entirely.

On the partner side, HIV treatment also prevents transmission: a partner living with HIV who takes their medicine and reaches an undetectable viral load can't transmit the virus sexually. Timely care matters on both ends of a relationship, so see how earlier HIV treatment strengthens what PrEP starts.

When to talk to a clinician

Reach out promptly if you've missed several doses and then had a possible exposure, if you started PrEP within the build-up window and had sex before protection peaked, if you notice symptoms of HIV seroconversion (fever, sore throat, rash, swollen glands within a few weeks of a possible exposure), or if you're simply not sure your regimen is right for how you're at risk. A clinician can confirm you're still HIV-negative, check that the dosing and format match your life, and switch you to an injectable if daily pills aren't sticking. Don't quietly stop PrEP without telling them, because that leaves a gap exactly when you may need cover most.

Keep exploring on EasySTD: whether PrEP is right for you, when to re-test and HIV/AIDS testing.